Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients

Inclusion Criteria: * Dialysis patients * A medical examination including physical examination and medical history as well as serological screening established acceptability for enrollment into the study. * Age: from 18 years onwards * Seronegative for anti- hepatitis antibodies Exclusion Criteria: * History of persistent hepatic, cardiac or respiratory disease * Any acute disease at the moment of entry into the study * Chronic alcohol consumption * Hepatomegaly, right upper quadrant pain or tenderness * Any treatment with coticosteroids or immunomodulating drugs * Known hypersensitivity to any component of the vaccine * Simultaneous participation in any other clinical trial